- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.07. | Bullion Gold Resources Corp (2): Bullion Gold private placement | 1 | Stockwatch | ||
| 10.07. | Bullion Gold Resources Corp (2): Bullion's Bousquet optionee Olympio continues drilling | 1 | Stockwatch | ||
| 09.07. | Bullion Gold Resources Corporation: Bullion Gold Reports Olympio Metals Continues Drilling Program on Bousquet Beyond the Initial Planned Program | 267 | Newsfile | Montreal, Quebec--(Newsfile Corp. - July 9, 2025) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Company") announces that its Australian partner Olympio Metals is continuing its... ► Artikel lesen | |
| 04.07. | Bullion Gold Resources Corp (2): Bullion Gold shareholders OK all resolutions at AGM | 4 | Stockwatch | ||
| BULLION GOLD RESOURCES Aktie jetzt für 0€ handeln | |||||
| 04.07. | Bullion Gold Resources Corporation: Bullion Gold Announces Results of Annual General Meeting | 535 | Newsfile | Montreal, Quebec--(Newsfile Corp. - July 3, 2025) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or "the Company") is pleased to announce that shareholders have approved of all resolutions... ► Artikel lesen | |
| 03.07. | Bullion Gold Resources Corp (2): Bullion Gold's Bousquet intersects visible gold | 1 | Stockwatch | ||
| 02.07. | Bullion Gold Resources Corporation: Exploration Work Advances on Bousquet, Bodo, and Langlade Projects | 368 | Newsfile | Montreal, Quebec--(Newsfile Corp. - July 2, 2025) - Bullion Gold Resources (TSXV: BGD) ("Bullion Gold" or "The Company") is pleased to provide an update to its shareholders and the public regarding... ► Artikel lesen | |
| 21.06. | Bullion Gold Resources Corp (2): Bullion Gold acquisition of Cadillac extension project | 2 | Stockwatch | ||
| 19.06. | Bullion Gold Resources Corp (2): Bullion Gold closes Cadillac Extension acquisition | 1 | Stockwatch | ||
| 18.06. | Bullion Gold Resources Corporation: Bullion Gold Completes the Acquisition of the Cadillac Extension (Langlade) Project | 454 | Newsfile | Montreal, Quebec--(Newsfile Corp. - June 18, 2025) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Company") is pleased to announce that it has closed the transaction to acquire... ► Artikel lesen | |
| 05.06. | Bullion Gold Resources Corp (2): Bullion Gold Resources private placement | 1 | Stockwatch | ||
| 05.06. | Bullion Gold Resources Corp (2): Bullion Gold private placement | 1 | Stockwatch | ||
| 03.06. | Bullion Gold Resources Corporation: Bullion Gold Begins Exploration Work on Bodo | 662 | Newsfile | Montreal, Quebec--(Newsfile Corp. - June 3, 2025) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Company") is pleased to announce the imminent launch of a second exploration program... ► Artikel lesen | |
| 09.05. | Bullion Gold Resources Corp (2): Bullion Gold signs LOI for Cadillac Extension project | 1 | Stockwatch | ||
| 08.05. | Bullion Gold Resources Corporation: Bullion Gold Acquires the Cadillac Extension (Langlade) Project | 243 | Newsfile | Montreal, Quebec--(Newsfile Corp. - May 8, 2025) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Company") is pleased to announce the signing of a letter of intent to acquire 100%... ► Artikel lesen | |
| 04.04. | Bullion Gold Resources Corp (2): Bullion receives TSX-V approval for Bousquet option | 1 | Stockwatch | ||
| 04.04. | Bullion Gold Resources Corporation: Bullion Gold Completes Transaction on Bousquet Property with Olympio Metals and Closes Financing | 1.669 | Newsfile | Montreal, Quebec--(Newsfile Corp. - April 4, 2025) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or "the Company") announces that the option agreement on the Bousquet property with Olympio... ► Artikel lesen | |
| 28.03. | Bullion Gold Resources Corp (2): Bullion Gold sale of option for Bousquet | 1 | Stockwatch | ||
| 18.03. | Bullion Gold Resources Corp (2): Bullion Gold signs option agreement with Olympio | 1 | Stockwatch | ||
| 18.03. | Bullion Gold Resources Corporation: Bullion Gold Signs Option Agreement with Olympio Metals for the Bousquet Project | 487 | Newsfile | Montreal, Quebec--(Newsfile Corp. - March 18, 2025) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or "the Company") announces the signing of an option agreement with Olympio Metals ("Olympio"... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,100 | +4,23 % | EQS-Adhoc: Evotec SE: Evotec passt Umsatzprognose an und bestätigt Gewinnprognose | EQS-Ad-hoc: Evotec SE / Schlagwort(e): Prognoseänderung
Evotec SE passt Umsatzprognose an und bestätigt Gewinnprognose
21.07.2025 / 11:25 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,255 | 0,00 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
| IMMUNOVANT | 18,320 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
| QIAGEN | 43,500 | +1,80 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 14,630 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
| JANUX THERAPEUTICS | 25,970 | 0,00 % | Raymond James startet Coverage für Janux Therapeutics mit "Outperform"-Rating | ||
| VERVE THERAPEUTICS | 11,130 | 0,00 % | Lilly completes tender offer for Verve Therapeutics shares | ||
| VIR BIOTECHNOLOGY | 5,760 | 0,00 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
| SANA BIOTECHNOLOGY | 5,125 | 0,00 % | Citi Maintained a Buy Rating on Sana Biotechnology (SANA) | ||
| BEAM THERAPEUTICS | 20,960 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 27,545 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 14,950 | 0,00 % | EU Grants Marketing Authorization For KOSTAIVE To CSL And Arcturus Therapeutics | CANBERA (dpa-AFX) - Biotechnology firm CSL Ltd. (CSL.AX, CMXHF.PK) and sa-mRNA pioneer Arcturus Therapeutics Ltd. (ARCT) announced Friday that the European Commission has granted marketing authorization... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,310 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| UPSTREAM BIO | 13,350 | 0,00 % | Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) | - Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for... ► Artikel lesen | |
| VALNEVA | 3,280 | -4,65 % | BioTech wird zu Gold: Wer schluckt wen oder was? Auf der Liste sind Evotec, BioNxt, Valneva und Formycon! | Der BioTech-Sektor blickt mit Argusaugen auf das Zinsniveau der Notenbanken. Aktuell allerdings scheint die Inflation noch etwas zu hoch, um massive Senkungen zu erwarten. So hat auch die EZB gestern... ► Artikel lesen |
Das Unternehmen BULLION GOLD RESOURCES CORPORATION kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BULLION GOLD RESOURCES CORPORATION finden Sie auf Wallstreet Online.